Page 223 - congress

POSTER PRESENTATION / POSTER SUNUM

Searching for Future Solutions in the Past: Analysis of Medicinal Plants in
Veterinary Pharmacology Textbook of Prof. Nurettin Mazhar Öktel

Serra Berin ÇANDIR Çiğdem BİLGİ Begüm YURDAKÖK-DİKMEN
2
1,*
3
Alvaro M. Fdez-Blanco BARRETO Liliana Susy Vargas MURGA
5
4
Theresa SCHLITTENLACHER Marta MENDEL Michael WALKENHORST 6
6
7

1 Ankara University, Graduate School of Health Sciences, Veterinary Pharmacology and
Toxicology, Ankara, TÜRKİYE
2 İzmir Institute of Technology, Department of Bioengineering, İzmir, TÜRKIYE
3 Ankara University Faculty of Veterinary Medicine, Department of Pharmacology and
Toxicology, Ankara, TÜRKIYE
4 School of Agricultural Engineering, University of Seville, Sevilla, SPAIN
5 University of Girona, Agri-Food Technology Department, Girona, SPAIN
6 Research Institute of Organic Agriculture (FiBL), Frick, SWITZERLAND
7 Warsaw University of Life Sciences, Faculty of Veterinary Medicine, Department of
Pharmacology and Toxicology, Warsaw, POLAND

*Correspound Author: dvmserraberin@gmail.com

At present, medicinal plants used in veterinary medicine in our country cannot be
authorized as veterinary medicinal products; due to the requirement that efficacy and toxicity

data must be demonstrated under GLP conditions in the relevant animal species, most

products are placed on the market only as complementary feed or feed additives. This
situation leads to the fact that the health effects indicated on the packaging of the products

are generally based on declaration, creating a significant gap in terms of standardization.
The MedPlants4Vet (CA22109) COST Action aims to investigate medicinal plants used in

veterinary medicine on a scientific basis, to evaluate their safety and efficacy, and to
integrate Europe’s traditional knowledge with modern veterinary pharmacology. Within this

scope, it is intended to reveal the place of medicinal plants used in veterinary medicine in
historical sources, thereby providing a scientific basis for evaluating these plants within

modern authorization processes through a “simplified registration (fast-track registration)”
approach. In the European Union (particularly in human medicine), accelerated pathways

similar to fast-track for herbal medicinal products are covered by authorization processes

220